SGLT2 inhibitor study for kidney disease and type 2 diabetes
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic kidney disease (CKD) with a kidney function score (eGFR) above 20 mL/min/1.73m², OR
- You have type 2 diabetes mellitus (T2DM).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study looks at how SGLT2 inhibitor medications (a type of diabetes drug) protect the kidneys in people with type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to understand the protective effects, which could help improve future treatments.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Hear when a new Implementation Research trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.